R Largillier
Overview
Explore the profile of R Largillier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
678
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harter P, Marth C, Mouret-Reynier M, Cropet C, Lorusso D, Guerra-Alia E, et al.
Ann Oncol
. 2024 Nov;
36(2):185-196.
PMID: 39528049
Background: The use of first-line poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is increasing in advanced ovarian cancer. Understanding the efficacy of first subsequent therapy (FST) in patients experiencing disease progression...
2.
Chamorey E, Barriere J, Ferrero J, Largillier R
Ann Oncol
. 2020 Jun;
20(1):193-194.
PMID: 32560009
No abstract available.
3.
Chamorey E, Barriere J, Ferrero J, Largillier R
Ann Oncol
. 2020 Jun;
20(1):189-190.
PMID: 32560008
No abstract available.
4.
Saint A, Viotti J, Borchiellini D, Hoch B, Raimondi V, Hebert C, et al.
Support Care Cancer
. 2019 Jul;
28(4):1639-1647.
PMID: 31278463
Purpose: Anemia is common in oncology and negatively impacts quality of life. However, there is lack of knowledge about iron deficiency (ID) epidemiology. The aim of this study was to...
5.
Follana P, Barriere J, Chamorey E, Largillier R, Dadone B, Mari V, et al.
Oncology
. 2014 Mar;
86(3):143-51.
PMID: 24577186
Background: Elderly patients with metastatic breast cancer have a prognosis and outcome that may be dependent on a host of factors. Patients And Methods: We retrospectively analyzed 401 female breast...
6.
Pautier P, Floquet A, Gladieff L, Bompas E, Ray-Coquard I, Piperno-Neumann S, et al.
Ann Oncol
. 2012 Nov;
24(4):1099-104.
PMID: 23139262
Background: There is no proven benefit of adjuvant treatment of uterine sarcoma (US). SARCGYN phase III study compared adjuvant polychemotherapy followed by pelvic radiotherapy (RT) (arm A) versus RT alone...
7.
Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, et al.
Br J Cancer
. 2012 Jul;
107(4):588-91.
PMID: 22836511
Background: The CALYPSO phase III trial compared CD (carboplatin-pegylated liposomal doxorubicin (PLD)) with CP (carboplatin-paclitaxel) in patients with platinum-sensitive recurrent ovarian cancer (ROC). Overall survival (OS) data are now mature....
8.
Goncalves A, Gilabert M, Francois E, Dahan L, Perrier H, Lamy R, et al.
Ann Oncol
. 2012 Jul;
23(11):2799-2805.
PMID: 22771827
Background: Sorafenib is an oral anticancer agent targeting Ras-dependent signaling and angiogenic pathways. A phase I trial demonstrated that the combination of gemcitabine and sorafenib was well tolerated and had...
9.
Ferrero J, Largillier R, Michel C, Amiot V, Milano G, Hebert C, et al.
Oncology
. 2011 Oct;
81(2):73-8.
PMID: 21968516
Background: Despite current treatment options, metastatic breast cancer (MBC) remains essentially incurable, requiring research on new drugs or combinations to improve survival and quality of life. Patients And Methods: This...
10.
Lortholary A, Largillier R, Weber B, Gladieff L, Alexandre J, Durando X, et al.
Ann Oncol
. 2011 May;
23(2):346-52.
PMID: 21562072
Background: Platinum rechallenge or weekly topotecan in combination have not been evaluated in randomized trials for resistant recurrent ovarian cancer (ROC). Methods: Patients with ROC after first- or second-line treatment...